Blood autoantibodies against tumor-associated antigens as biomarkers in early detection of colorectal cancer

Cancer Letters

Volumn 346, Issue 2, 2014, Pages 178-187

  Chen, Hongda ^a   Werner, Simone ^a   Tao, Sha ^a   Zörnig, Inka ^b   Brenner, Hermann ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Autoantibodies; Biomarker; Colorectal cancer; Early detection; Systematic review

Indexed keywords

AUTOANTIBODY; TUMOR ANTIGEN; CANCER ANTIBODY; TUMOR MARKER;

ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; COLORECTAL CANCER; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; PROTEIN MICROARRAY; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; SYSTEMATIC REVIEW; WESTERN BLOTTING; ANTIBODY SPECIFICITY; BLOOD; COLORECTAL NEOPLASMS; IMMUNOLOGY; PROCEDURES;

ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTIGENS, NEOPLASM; AUTOANTIBODIES; COLORECTAL NEOPLASMS; EARLY DETECTION OF CANCER; HUMANS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896139983     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.01.007     Document Type: Review

References (78)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Lee C.S., Ronan L., O'Morain C., McNamara D. Screening for colorectal cancer: what fits best?. Expert Rev. Gastroenterol. Hepatol. 2012, 6:301-312.
3. Pawa N., Arulampalam T., Norton J.D. Screening for colorectal cancer: established and emerging modalities. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:711-722.
4. Brenner H., Tao S. Superior diagnostic performance of faecal immunochemical tests for haemoglobin in a head-to-head comparison with guaiac based faecal occult blood test among 2235 participants of screening colonoscopy. Eur. J. Cancer 2013, 49:3049-3054.
5. Yao Y., Fan Y., Wu J., Wan H., Wang J., Lam S., Lam W.L., Girard L., Gazdar A.F., Wu Z., Zhou Q. Potential application of non-small cell lung cancer-associated autoantibodies to early cancer diagnosis. Biochem. Biophys. Res. Commun. 2012, 423:613-619.
6. Gnjatic S., Ritter E., Buchler M.W., Giese N.A., Brors B., Frei C., Murray A., Halama N., Zornig I., Chen Y.T., Andrews C., Ritter G., Old L.J., Odunsi K., Jager D. Seromic profiling of ovarian and pancreatic cancer. Proc. Natl. Acad. Sci. USA 2010, 107:5088-5093.
7. Chatterjee M., Mohapatra S., Ionan A., Bawa G., Ali-Fehmi R., Wang X., Nowak J., Ye B., Nahhas F.A., Lu K., Witkin S.S., Fishman D., Munkarah A., Morris R., Levin N.K., Shirley N.N., Tromp G., Abrams J., Draghici S., Tainsky M.A. Diagnostic markers of ovarian cancer by high-throughput antigen cloning and detection on arrays. Cancer Res. 2006, 66:1181-1190.
8. Caron M., Choquet-Kastylevsky G., Joubert-Caron R. Cancer immunomics using autoantibody signatures for biomarker discovery. Mol. Cell. Proteomics 2007, 6:1115-1122.
9. Brichory F.M., Misek D.E., Yim A.M., Krause M.C., Giordano T.J., Beer D.G., Hanash S.M. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc. Natl. Acad. Sci. USA 2001, 98:9824-9829.
10. Wang X., Yu J., Sreekumar A., Varambally S., Shen R., Giacherio D., Mehra R., Montie J.E., Pienta K.J., Sanda M.G., Kantoff P.W., Rubin M.A., Wei J.T., Ghosh D., Chinnaiyan A.M. Autoantibody signatures in prostate cancer. N. Engl. J. Med. 2005, 353:1224-1235.
11. Tsunemi S., Nakanishi T., Fujita Y., Bouras G., Miyamoto Y., Miyamoto A., Nomura E., Takubo T., Tanigawa N. Proteomics-based identification of a tumor-associated antigen and its corresponding autoantibody in gastric cancer. Oncol. Rep. 2010, 23:949-956.
12. Mosolits S., Harmenberg U., Ruden U., Ohman L., Nilsson B., Wahren B., Fagerberg J., Mellstedt H. Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma. Cancer Immunol. Immunother. 1999, 47:315-320.
13. Tang R., Ko M.C., Wang J.Y., Changchien C.R., Chen H.H., Chen J.S., Hsu K.C., Chiang J.M., Hsieh L.L. Humoral response to p53 in human colorectal tumors: a prospective study of 1,209 patients. Int. J. Cancer 2001, 94:859-863.
14. Kojima T., Yoshikawa K., Matsui T., Kodera Y., Kojima H. Titration of serum CEA, p53 antibodies and CEA-IgM complexes in patients with colorectal cancer. Mol. Med. Rep. 2009, 2:477-480.
15. Hammel P., Boissier B., Chaumette M.T., Piedbois P., Rotman N., Kouyoumdjian J.C., Lubin R., Delchier J.C., Soussi T. Detection and monitoring of serum p53 antibodies in patients with colorectal cancer. Gut 1997, 40:356-361.
16. Suppiah A., Alabi A., Madden L., Hartley J.E., Monson J.R., Greenman J. Anti-p53 autoantibody in colorectal cancer: prognostic significance in long-term follow-up. Int. J. Colorectal Dis. 2008, 23:595-600.
17. Muller M., Meyer M., Schilling T., Ulsperger E., Lehnert T., Zentgraf H., Stremmel W., Volkmann M., Galle P.R. Testing for anti-p53 antibodies increases the diagnostic sensitivity of conventional tumor markers. Int. J. Oncol. 2006, 29:973-980.
18. Pedersen J.W., Blixt O., Bennett E.P., Tarp M.A., Dar I., Mandel U., Poulsen S.S., Pedersen A.E., Rasmussen S., Jess P., Clausen H., Wandall H.H. Seromic profiling of colorectal cancer patients with novel glycopeptide microarray. Int. J. Cancer 2011, 128:1860-1871.
19. Chang W., Wu L., Cao F., Liu Y., Ma L., Wang M., Zhao D., Li P., Zhang Q., Tan X., Yu Y., Lou Z., Zhao J., Zhang H., Fu C., Cao G. Development of autoantibody signatures as biomarkers for early detection of colorectal carcinoma. Clin. Cancer Res. 2011, 17:5715-5724.
20. Chen J.S., Chen K.T., Fan W.C., Yu J.S., Chang Y.S., Chan E.C. Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer. Clin. Chem. Lab. Med. 2010, 48:719-725.
21. Lechpammer M., Lukac J., Lechpammer S., Kovacevic D., Loda M., Kusic Z. Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy. Int. J. Colorectal Dis. 2004, 19:114-120.
22. Frenkel K., Karkoszka J., Glassman T., Dubin N., Toniolo P., Taioli E., Mooney L.A., Kato I. Serum autoantibodies recognizing 5-hydroxymethyl-2'-deoxyuridine, an oxidized DNA base, as biomarkers of cancer risk in women. Cancer Epidemiol. Biomarkers Prev. 1998, 7:49-57.
23. Pedersen J.W., Gentry-Maharaj A., Fourkala E.O., Dawnay A., Burnell M., Zaikin A., Pedersen A.E., Jacobs I., Menon U., Wandall H.H. Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer. Br. J. Cancer 2013, 108:107-114.
24. Wu M., Mao C., Chen Q., Cu X.W., Zhang W.S. Serum p53 protein and anti-p53 antibodies are associated with increased cancer risk: a case-control study of 569 patients and 879 healthy controls. Mol. Biol. Rep. 2010, 37:339-343.
25. Babel I., Barderas R., Diaz-Uriarte R., Martinez-Torrecuadrada J.L., Sanchez-Carbayo M., Casal J.I. Identification of tumor-associated autoantigens for the diagnosis of colorectal cancer in serum using high density protein microarrays. Mol. Cell. Proteomics 2009, 8:2382-2395.
26. Babel I., Barderas R., Diaz-Uriarte R., Moreno V., Suarez A., Fernandez-Acenero M.J., Salazar R., Capella G., Casal J.I. Identification of MST1/STK4 and SULF1 proteins as autoantibody targets for the diagnosis of colorectal cancer by using phage microarrays. Mol. Cell. Proteomics 2011, 10. M110 001784.
27. Ran Y., Hu H., Zhou Z., Yu L., Sun L., Pan J., Liu J., Yang Z. Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin. Cancer Res. 2008, 14:2696-2700.
28. He Y., Wu Y., Mou Z., Li W., Zou L., Fu T., Zhang A., Xiang D., Xiao H., Wang X. Proteomics-based identification of HSP60 as a tumor-associated antigen in colorectal cancer. Proteomics Clin. Appl. 2007, 1:336-342.
29. Suzuki H., Graziano D.F., McKolanis J., Finn O.J. T cell-dependent antibody responses against aberrantly expressed cyclin B1 protein in patients with cancer and premalignant disease. Clin. Cancer Res. 2005, 11:1521-1526.
30. Reipert B.M., Tanneberger S., Pannetta A., Bedosti M., Poell M., Zimmermann K., Stellamor M.T. Increase in autoantibodies against Fas (CD95) during carcinogenesis in the human colon: a hope for the immunoprevention of cancer?. Cancer Immunol. Immunother. 2005, 54:1038-1042.
31. Song M.H., Ha J.M., Shin D.H., Lee C.H., Old L., Lee S.Y. KP-CoT-23 (CCDC83) is a novel immunogenic cancer/testis antigen in colon cancer. Int. J. Oncol. 2012, 41:1820-1826.
32. Kanojia D., Garg M., Gupta S., Gupta A., Suri A. Sperm-associated antigen 9 is a novel biomarker for colorectal cancer and is involved in tumor growth and tumorigenicity. Am. J. Pathol. 2011, 178:1009-1020.
33. Chen J.S., Kuo Y.B., Chou Y.P., Chan C.C., Fan C.W., Chen K.T., Huang Y.S., Chan E.C. Detection of autoantibodies against Rabphilin-3A-like protein as a potential biomarker in patient's sera of colorectal cancer. Clin. Chim. Acta 2011, 412:1417-1422.
34. Yu D.H., Li J.H., Wang Y.C., Xu J.G., Pan P.T., Wang L. Serum anti-p53 antibody detection in carcinomas and the predictive values of serum p53 antibodies, carcino-embryonic antigen and carbohydrate antigen 12-5 in the neoadjuvant chemotherapy treatment for III stage non-small cell lung cancer patients. Clin. Chim. Acta 2011, 412:930-935.
35. Chen X., Dong K., Long M., Lin F., Wang X., Wei J., Ren J., Zhang H. Serum anti-AEG-1 auto-antibody is a potential novel biomarker for malignant tumors. Oncol. Lett. 2012, 4:319-323.
36. Hanafusa T., Mohamed A.E., Domae S., Nakayama E., Ono T. Serological identification of Tektin5 as a cancer/testis antigen and its immunogenicity. BMC Cancer 2012, 12:520.
37. Tao S., Hundt S., Haug U., Brenner H. Sensitivity estimates of blood-based tests for colorectal cancer detection: impact of overrepresentation of advanced stage disease. Am. J. Gastroenterol. 2011, 106:242-253.
38. Wu J., Qiu T., Pan P., Yu D., Ju Z., Qu X., Gao X., Mao C., Wang L. Detection of serum anti-P53 antibodies from patients with colorectal cancer in China using a combination of P53- and phage-ELISA: correlation to clinical parameters. Asian Pac. J. Cancer Prev. 2011, 12:2921-2924.
39. Kojima T., Matsui T., Fujimitsu Y., Kojima H., Uno H., Hiramatsu K., Inagaki H., Oda K., Ishiyama A., Iwata N., Nakayama G., Kodera Y. Titration of serum CEA, p53 antibodies and CEA-IgM complexes in 142 patients with colorectal cancer and 150 healthy blood donors. Ann. Cancer Res. Ther. 2011, 19:15-19.
40. Chan C.C., Fan C.W., Kuo Y.B., Chen Y.H., Chang P.Y., Chen K.T., Hung R.P., Chan E.C. Multiple serological biomarkers for colorectal cancer detection. Int. J. Cancer 2010, 126:1683-1690.
41. Liu W., Wang P., Li Z., Xu W., Dai L., Wang K., Zhang J. Evaluation of tumour-associated antigen (TAA) miniarray in immunodiagnosis of colon cancer. Scand. J. Immunol. 2009, 69:57-63.
42. Chen Y., Lin P., Qiu S.M., Peng X.X., Looi K., Farquhar M.G., Zhang J.Y. Autoantibodies to Ca2+ binding protein Calnuc is a potential marker in colon cancer detection. Int. J. Oncol. 2007, 30:1137-1144.
43. Looi K., Megliorino R., Shi F.D., Peng X.X., Chen Y., Zhang J.Y. Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol. Rep. 2006, 16:1105-1110.
44. Chang S.C., Lin J.K., Lin T.C., Liang W.Y. Genetic alteration of p53, but not overexpression of intratumoral p53 protein, or serum p53 antibody is a prognostic factor in sporadic colorectal adenocarcinoma. Int. J. Oncol. 2005, 26:65-75.
45. Zhang J.Y., Casiano C.A., Peng X.X., Koziol J.A., Chan E.K.L., Tan E.M. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol. Biomarkers Prev. 2003, 136-143.
46. Shimada H., Ochiai T., Nomura F. Titration of serum p53 antibodies in 1085 patients with various types of malignant tumors a multiinstitutional analysis by the Japan p53 Antibody Research Group. Cancer 2003, 97:682-689.
47. Scanlan M.J., Welt S., Gordon C.M., Chen Y.T., Gure A.O., Stockert E., Jungbluth A.A., Ritter G., Jager D., Jager E., Knuth A., Old L.J. Cancer-related serological recognition of human colon cancer: identification of potential diagnostic and immunotherapeutic targets. Cancer Res. 2002, 62:4041-4047.
48. Broll R., Duchrow M., Oevermann E., Wellm C., Schwandner O., Schimmelpenning H., Roblick U.J., Bruch H.P., Windhovel U. P53 autoantibodies in sera of patients with a colorectal cancer and their association to p53 protein concentration and p53 immunohistochemistry in tumor tissue. Int. J. Colorectal Dis. 2001, 16:22-27.
49. Hallak R., Mueller J., Lotter O., Gansauge S., Gansauge F., El-Deen Jumma M., Montenarh M., Safi F., Beger H. P53 genetic alterations, protein expression and autoantibodies in human colorectal carcinoma: a comparative study. Int. J. Oncol. 1998, 12:785-791.
50. Angelopoulou K., Diamandis E.P., Sutherland D.J., Kellen J.A., Bunting P.S. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int. J. Cancer 1994, 58:480-487.
51. Ben-Mahrez K., Sorokine I., Thierry D., Kawasumi T., Ishii S., Salmon R., Kohiyama M. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int. J. Cancer 1990, 46:35-38.
52. Wu X.J., Fang Y.J., Lin J.Z., Lu Z.H., Li L.R., Chen G., Ding P.R., Kong L.H., Pan Z.Z., Wan D.S. Circulating antibodies to carcinoembryonic antigen related to improved recurrence-free survival of patients with colorectal carcinoma. J. Int. Med. Res. 2011, 39:838-845.
53. Albanopoulos K., Armakolas A., Konstadoulakis M.M., Leandros E., Tsiompanou E., Katsaragakis S., Alexiou D., Androulakis G. Prognostic significance of circulating antibodies against carcinoembryonic antigen (anti-CEA) in patients with colon cancer. Am. J. Gastroenterol. 2000, 95:1056-1061.
54. Konstadoulakis M.M., Syrigos K.N., Albanopoulos C., Mayers G., Golematis B. The presence of anti-carcinoembryonic antigen (CEA) antibodies in the sera of patients with gastrointestinal malignancies. J. Clin. Immunol. 1994, 14:310-313.
55. Zhang J.Y., Chan E.K., Peng X.X., Lu M., Wang X., Mueller F., Tan E.M. Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin. Immunol. 2001, 100:149-156.
56. Liu W., Li Z., Xu W., Wang Q., Yang S. Humoral autoimmune response to IGF2 mRNA-binding protein (IMP2/p62) and its tissue-specific expression in colon cancer. Scand. J. Immunol. 2013, 77:255-260.
57. Megliorino R., Shi F.D., Peng X.X., Wang X., Chan E.K., Tan E.M., Zhang J.Y. Autoimmune response to anti-apoptotic protein survivin and its association with antibodies to p53 and c-myc in cancer detection. Cancer Detect. Prev. 2005, 29:241-248.
58. Silk A.W., Schoen R.E., Potter D.M., Finn O.J. Humoral immune response to abnormal MUC1 in subjects with colorectal adenoma and cancer. Mol. Immunol. 2009, 47:52-56.
59. Nakamura H., Hinoda Y., Nakagawa N., Makiguchi Y., Itoh F., Endo T., Imai K. Detection of circulating anti-MUC1 mucin core protein antibodies in patients with colorectal cancer. J. Gastroenterol. 1998, 33:354-361.
60. Chen J.S., Chou Y.P., Chen K.T., Hung R.P., Yu J.S., Chang Y.S., Chan E.C. Detection of annexin A autoantibodies in sera from colorectal cancer patients. J. Clin. Gastroenterol. 2011, 45:125-132.
61. Fan C.W., Chan C.C., Chen K.T., Twu J., Huang Y.S., Han C.L., Chen Y.J., Yu J.S., Chang Y.S., Kuo Y.B., Chan E.C. Identification of SEC61beta and its autoantibody as biomarkers for colorectal cancer. Clin. Chim. Acta 2011, 412:887-893.
62. Kocer B., McKolanis J., Soran A. Humoral immune response to MUC5AC in patients with colorectal polyps and colorectal carcinoma. BMC Gastroenterol. 2006, 6:4.
63. Kiyamova R., Garifulin O., Gryshkova V., Kostianets O., Shyian M., Gout I., Filonenko V. Preliminary study of thyroid and colon cancers-associated antigens and their cognate autoantibodies as potential cancer biomarkers. Biomarkers 2012, 17:362-371.
64. Nam M.J., Madoz-Gurpide J., Wang H., Lescure P., Schmalbach C.E., Zhao R., Misek D.E., Kuick R., Brenner D.E., Hanash S.M. Molecular profiling of the immune response in colon cancer using protein microarrays: occurrence of autoantibodies to ubiquitin C-terminal hydrolase L3. Proteomics 2003, 3:2108-2115.
65. Rimm D.L., Holland T.E., Morrow J.S., Anderson J.M. Autoantibodies specific for Villin found in patients with colon-cancer and other colitides. Digest Dis. Sci. 1995, 40:389-395.
66. Li Y., Jiang T., Zhang J., Zhang B., Yang W., You G., Xu K., Wu J., Luo C., Song S.W. Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies. Ann. Oncol. 2012, 23:2415-2422.
67. Syrigos K.N., Charalampopoulos A., Pliarchopoulou K., Syrigou E.I., Avuzuklidou M., Manouras A., Leandros M. Prognostic significance of autoantibodies against tropomyosin in patients with colorectal adenocarcinoma. Hybridoma 1999, 18:543-546.
68. He Y., Mou Z., Li W., Liu B., Fu T., Zhao S., Xiang D., Wu Y. Identification of IMPDH2 as a tumor-associated antigen in colorectal cancer using immunoproteomics analysis. Int. J. Colorectal Dis. 2009, 24:1271-1279.
69. Takahashi M., Chen W., Byrd D.R., Disis M.L., Huseby E.S., Qin H., McCahill L., Nelson H., Shimada H., Okuno K., et al. Antibody to ras proteins in patients with colon cancer. Clin. Cancer Res. 1995, 1:1071-1077.
70. Kamei M., Kato M., Mochizuki K., Kuroda K., Sato S., Hashizume S., Yasumoto K., Murakami H., Nomoto K. Serodiagnosis of cancers by Elisa of Antihistone H2b Antibody. Biotherapy 1992, 4:17-22.
71. Fujita Y., Nakanishi T., Miyamoto Y., Hiramatsu M., Mabuchi H., Miyamoto A., Shimizu A., Takubo T., Tanigawa N. Proteomics-based identification of autoantibody against heat shock protein 70 as a diagnostic marker in esophageal squamous cell carcinoma. Cancer Lett. 2008, 263:280-290.
72. Jiang B., Ren T., Dong B., Qu L., Jin G., Li J., Qu H., Meng L., Liu C., Wu J., Shou C. Peptide mimic isolated by autoantibody reveals human arrest defective 1 overexpression is associated with poor prognosis for colon cancer patients. Am. J. Pathol. 2010, 177:1095-1103.
73. Xia Q., Kong X.T., Zhang G.A., Hou X.J., Qiang H., Zhong R.Q. Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. Biochem. Biophys. Res. Commun. 2005, 330:526-532.
74. Song M.H., Ha J.C., Lee S.M., Park Y.M., Lee S.Y. Identification of BCP-20 (FBXO39) as a cancer/testis antigen from colon cancer patients by SEREX. Biochem. Biophys. Res. Commun. 2011, 408:195-201.
75. Song J., Sun X., Sokoll L.J., Maki M., Tian Y., Chan D.W., Zhang Z. Detection of autoantibodies to Annexin A11 in different types of human cancer. Clin. Proteom. 2009, 5:125-131.
76. Shebzukhov Y.V., Koroleva E.P., Khlgatian S.V., Belousov P.V., Kuz'mina K.E., Radko B.V., Longpre F., Lagarkova M.A., Kadachigova T.S., Gurova O.V., Meshcheryakov A.A., Lichinitser M.R., Knuth A., Jager E., Kuprash D.V., Nedospasov S.A. Antibody response to a non-conserved C-terminal part of human histone deacetylase 3 in colon cancer patients. Int. J. Cancer 2005, 117:800-806.
77. Xu Q.W., Zhao W., Wang Y., Sartor M.A., Han D.M., Deng J., Ponnala R., Yang J.Y., Zhang Q.Y., Liao G.Q., Qu Y.M., Li L., Liu F.F., Zhao H.M., Yin Y.H., Chen W.F., Zhang Y., Wang X.S. An integrated genome-wide approach to discover tumor-specific antigens as potential immunologic and clinical targets in cancer. Cancer Res. 2012, 72:6351-6361.
78. Koziol J.A., Zhang J.Y., Casiano C.A., Peng X.X., Shi F.D., Feng A.C., Chan E.K.L., Tan E.M. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin. Cancer Res. 2003, 9:5120-5126.